| Literature DB >> 29093353 |
Motoki Endo1, Yasuo Haruyama2, Go Muto3, Kosuke Kiyohara1, Tetsuya Mizoue4, Noriko Kojimahara1, Naohito Yamaguchi1.
Abstract
BACKGROUND: Few studies have investigated the work continuance rate among cancer survivors after return to work (RTW). The objective of this study was to clarify work sustainability after RTW among Japanese male cancer survivors.Entities:
Keywords: cancer survivors; return to work (RTW); sick leave; work continuance rate; work sustainability
Mesh:
Year: 2017 PMID: 29093353 PMCID: PMC5800885 DOI: 10.2188/jea.JE20160152
Source DB: PubMed Journal: J Epidemiol ISSN: 0917-5040 Impact factor: 3.211
Basic characteristics of the subjects in this study
| Cancer site | Total | Mean (SD) age, | Median duration of | Recurrent sick leave | Resigned | Median duration of work |
| Gastric | 234 | 52.9 (5.1) | 65 | 56 | 33 | 10.9 |
| Intestinal | 114 | 51.6 (6.0) | 81 | 43 | 4 | 8.3 |
| Lung | 104 | 53.6 (4.8) | 97 | 55 | 25 | 0.9 |
| Male genital | 66 | 52.4 (7.4) | 94 | 13 | 2 | — |
| Blood | 61 | 48.7 (8.0) | 198 | 32 | 1 | 3.8 |
| Hepatic, pancreatic | 45 | 54.4 (4.9) | 79 | 26 | 4 | 0.9 |
| Urinary | 43 | 52.3 (5.7) | 84 | 20 | 1 | 2.8 |
| Esophageal | 40 | 53.6 (3.9) | 94 | 21 | 5 | 1.5 |
| Other | 79 | 50.1 (7.7) | 114 | 34 | 1 | 7.1 |
| Total | 786 | 52.1 (6.1) | 93 | 300 | 76 | 4.5 |
RTW, return to work; SD, standard deviation.
Figure 1. Work continuance rates from the day of RTW using Kaplan-Meier survival analysis. RTW, return to work.
Figure 2. Work continuance rate from the day of RTW, stratified by cancer sites. RTW, return to work.
Cox regression model for the time to work sustainability failure
| Variables | Categories | Single variable analysis | Multivariable analysis | ||
| HR (95% CI) | Trend | HR (95% CI) | Trend | ||
| Age, years | <0.01 | 0.05 | |||
| <48 (ref) | 1 | 1 | |||
| 49–52 | 1.30 (0.96–1.77) | 1.19 (0.84–1.67) | |||
| 53–56 | 1.36 (1.02–1.81) | 1.32 (0.96–1.82) | |||
| >57 | 1.68 (1.22–2.31) | 1.71 (1.16–2.51) | |||
| Duration of sick leave, days | <0.01 | <0.01 | |||
| <60 (ref) | 1 | 1 | |||
| 61–180 | 1.52 (1.22–1.90) | 1.46 (1.15–1.87) | |||
| >181 | 2.17 (1.60–2.96) | 2.32 (1.54–3.49) | |||
| Cancer sites | |||||
| Gastric (ref) | 1 | 1 | |||
| Intestinal | 1.22 (0.86–1.73) | 1.12 (0.76–1.66) | |||
| Lung | 3.75 (2.76–5.09) | 3.31 (2.38–4.62) | |||
| Male genital | 0.65 (0.37–1.16) | 0.52 (0.29–0.92) | |||
| Blood | 1.85 (1.24–2.77) | 1.15 (0.70–1.88) | |||
| Hepatic, pancreatic | 3.43 (2.26–5.22) | 2.74 (1.72–4.36) | |||
| Urinary | 1.91 (1.19–3.08) | 1.90 (1.13–3.18) | |||
| Esophageal | 2.58 (1.66–4.00) | 2.30 (1.44–3.67) | |||
| Calendar year (year of sick leave) | |||||
| 2000–2003 (ref) | 1 | 1 | |||
| 2004–2007 | 0.93 (0.73–1.17) | 0.93 (0.72–1.20) | |||
| 2008–2011 | 1.22 (0.93–1.59) | 1.01 (0.74–1.37) | |||
| Company size | |||||
| ≥1000 employees (ref) | 1 | 1 | |||
| <1000 employees | 0.92 (0.66–1.27) | 0.81 (0.57–1.15) | |||
| Manager/non-manager | |||||
| Non-manager (ref) | 1 | 1 | |||
| Manager | 1.87 (1.26–2.77) | 1.82 (1.19–2.77) | |||
| Job title | |||||
| Desk worker (ref) | 1 | 1 | |||
| Manual worker | 0.76 (0.60–0.97) | 0.74 (0.58–0.95) | |||
CI, confidence interval; HR, hazard ratio.
aAdjustment for age, duration of sick leave, cancer sites, calendar year, company size, manager/non-manager, and job title.